Day One Biopharmaceuticals, Inc. (DAWN): A Bull Case Theory

We came across a bullish thesis on Day One Biopharmaceuticals, Inc. (DAWN) on Twitter by Pharmdca. In this article, we will summarize the bulls’ thesis on DAWN. Day One Biopharmaceuticals, Inc. (DAWN)’s share was trading at $8.60 as of March 4th.

5 Countries with the Highest Rate of Dementia

Miriam Doerr Martin Frommherz/Shutterstock.com

DAWN is an undervalued commercial-stage oncology company with a long-term target in the mid-$30s, driven by its total addressable market (TAM) and strong pipeline. Its lead drug, OJEMDA, has quickly...